ArticleNeurology and therapy2025

Societal Costs and Efficiency of Subcutaneous versus Intravenous Lecanemab in Early Alzheimer's Disease: A U.S. Cost Comparison Model.

Amir Abbas Tahami Monfared et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.